Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure

Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic  T. Cruzi Carriers

(2017) Carlos A. Morillo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Macromolecular biosynthetic parameters and metabolic profile in different life stages of Leishmania braziliensis: Amastigotes as a functionally less active stage

(2017) Marlene Jara et al.   PLoS One

Continual renewal and replication of persistentLeishmania majorparasites in concomitantly immune hosts

(2017) Michael A. Mandell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanisms of bacterial persistence during stress and antibiotic exposure

(2016) Alexander Harms et al.   SCIENCE

New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients

(2015) María Gabriela Álvarez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Plasmodium vivax Liver Stage Development and Hypnozoite Persistence in Human Liver-Chimeric Mice

(2015) Sebastian A. Mikolajczak et al.   Cell Host & Microbe

Advanced CUBIC protocols for whole-brain and whole-body clearing and imaging

(2015) Etsuo A Susaki et al.   Nature Protocols

Characterization of Metabolically Quiescent Leishmania Parasites in Murine Lesions Using Heavy Water Labeling

(2015) Joachim Kloehn et al.   PLoS Pathogens

Bioluminescence imaging of chronicTrypanosoma cruziinfections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection

(2014) Michael D. Lewis et al.   CELLULAR MICROBIOLOGY

Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas' Disease

(2014) Israel Molina et al.   NEW ENGLAND JOURNAL OF MEDICINE

CRISPR-Cas9-Mediated Single-Gene and Gene Family Disruption in Trypanosoma cruzi

(2014) D. Peng et al.   mBio

Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development

(2014) Carolina B. Moraes et al.   Scientific Reports

DNA damage signaling, impairment of cell cycle progression, and apoptosis triggered by 5-ethynyl-2′-deoxyuridine incorporated into DNA

(2013) Hong Zhao et al.   CYTOMETRY PART A

New, Combined, and Reduced Dosing Treatment Protocols Cure Trypanosoma cruzi Infection in Mice

(2013) J. M. Bustamante et al.   JOURNAL OF INFECTIOUS DISEASES

Benznidazole Shortage Makes Chagas Disease a Neglected Tropical Disease in Developed Countries: Data from Spain

(2012) Miriam Navarro et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Benznidazole-Resistance in Trypanosoma cruzi Is a Readily Acquired Trait That Can Arise Independently in a Single Population

(2012) Ana Maria Mejia et al.   JOURNAL OF INFECTIOUS DISEASES

Current status of Chagas disease chemotherapy

(2011) Paulo MM Guedes et al.   Expert Review of Anti-Infective Therapy

Dormancy in mammalian malaria

(2011) Miles B. Markus   TRENDS IN PARASITOLOGY

Impact of Aetiological Treatment on Conventional and Multiplex Serology in Chronic Chagas Disease

(2011) Rodolfo Viotti et al.   PLoS Neglected Tropical Diseases

Tolerance and Safety of Nifurtimox in Patients with Chronic Chagas Disease

(2010) Yves Jackson et al.   CLINICAL INFECTIOUS DISEASES

In Vitro and In Vivo High-Throughput Assays for the Testing of Anti-Trypanosoma cruzi Compounds

(2010) Adriana M. C. Canavaci et al.   PLoS Neglected Tropical Diseases

Feasibility, Drug Safety, and Effectiveness of Etiological Treatment Programs for Chagas Disease in Honduras, Guatemala, and Bolivia: 10-Year Experience of Médecins Sans Frontières

(2009) Oliver Yun et al.   PLoS Neglected Tropical Diseases

Further evidence of spontaneous cure in human Chagas disease

(2008) João Carlos Pinto Dias et al.   Revista da Sociedade Brasileira de Medicina Tropical